Temozolomide and radiotherapy versus radiotherapy alone in patients with glioblastoma, IDH-wildtype: post hoc analysis of the eortc randomized phase III CATNON trial
dc.contributor.author | Tesileanu, M. S. | |
dc.contributor.author | Sanson, M. | |
dc.contributor.author | Wick, W. | |
dc.contributor.author | Brandes, A. A. | |
dc.contributor.author | Clement, P. M. | |
dc.contributor.author | Erridge, S. C. | |
dc.contributor.author | Vogelbaum, M. A. | |
dc.contributor.author | Nowak, A. K. | |
dc.contributor.author | Baurain, J. F. | |
dc.contributor.author | Mason, W. P. | |
dc.contributor.author | Wheeler, H. | |
dc.contributor.author | Chinot, O. L. | |
dc.contributor.author | Gill, S. | |
dc.contributor.author | Grif, M. | |
dc.contributor.author | Rogers, L. | |
dc.contributor.author | Taal, W. | |
dc.contributor.author | Ruda, R. | |
dc.contributor.author | Weller, M. | |
dc.contributor.author | McBain, Catharine A | |
dc.contributor.author | van Linde, M. E. | |
dc.contributor.author | Aldape, K. | |
dc.contributor.author | Jenkins, R. B. | |
dc.contributor.author | Kros, J. M. | |
dc.contributor.author | Wesseling, P. | |
dc.contributor.author | von Deimling, A. | |
dc.contributor.author | Hoogstrate, Y. | |
dc.contributor.author | de Heer, I. | |
dc.contributor.author | Atmodimedjo, P. N. | |
dc.contributor.author | Dubbink, H. J. | |
dc.contributor.author | Brouwer, R. W. W. | |
dc.contributor.author | Ijcken, W. | |
dc.contributor.author | Cheung, K. J. | |
dc.contributor.author | Golfinopoulos, V. | |
dc.contributor.author | Baumert, B. G. | |
dc.contributor.author | Gorlia, T. | |
dc.contributor.author | French, P. J. | |
dc.contributor.author | van den Bent, M. J. | |
dc.date.accessioned | 2022-08-17T09:52:26Z | |
dc.date.available | 2022-08-17T09:52:26Z | |
dc.date.issued | 2022 | en |
dc.identifier.citation | Tesileanu MS, Sanson M, Wick W, Brandes AA, Clement PM, Erridge SC, et al. Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. Clinical Cancer Research. 2022 Jun;28(12):2527-35. PubMed PMID: WOS:000814512400001. Pubmed Central PMCID: 9297529. | en |
dc.identifier.pmid | 35275197 | en |
dc.identifier.doi | 10.1158/1078-0432.CCR-21-4283. | en |
dc.identifier.uri | http://hdl.handle.net/10541/625528 | |
dc.description.abstract | Purpose: In a post hoc analysis of the CATNON trial (NCT00626990), we explored whether adding temozolomide to radiotherapy improves outcome in patients with IDH1/2 wildtype (wt) anaplastic astrocytomas with molecular features of glioblastoma [redesignated as glioblastoma, isocitrate dehydrogenase-wildtype (IDH-wt) in the 2021 World Health Organization (WHO) classification of central nervous system tumors]. Patients and methods: From the randomized phase III CATNON study examining the addition of adjuvant and concurrent temozolomide to radiotherapy in anaplastic astrocytomas, we selected a subgroup of IDH1/2wt and H3F3Awt tumors with presence of TERT promoter mutations and/or EGFR amplifications and/or combined gain of chromosome 7 and loss of chromosome 10. Molecular abnormalities including MGMT promoter methylation status were determined by next-generation sequencing, DNA methylation profiling, and SNaPshot analysis. Results: Of the 751 patients entered in the CATNON study, 670 had fully molecularly characterized tumors. A total of 159 of these tumors met the WHO 2021 molecular criteria for glioblastoma, IDH-wt. Of these patients, 47 received radiotherapy only and 112 received a combination of radiotherapy and temozolomide. There was no added effect of temozolomide on either overall survival [HR, 1.19; 95% confidence interval (CI), 0.82-1.71] or progression-free survival (HR, 0.87; 95% CI, 0.61-1.24). MGMT promoter methylation was prognostic for overall survival, but was not predictive for outcome to temozolomide treatment either with respect to overall survival or progression-free survival. Conclusions: In this cohort of patients with glioblastoma, IDH-wt temozolomide treatment did not add benefit beyond that observed from radiotherapy, regardless of MGMT promoter status. These findings require a new well-powered prospective clinical study to explore the efficacy of temozolomide treatment in this patient population. | en |
dc.relation.url | https://dx.doi.org/10.1158/1078-0432.CCR-21-4283. | en |
dc.title | Temozolomide and radiotherapy versus radiotherapy alone in patients with glioblastoma, IDH-wildtype: post hoc analysis of the eortc randomized phase III CATNON trial | en |
dc.type | Article | en |
dc.contributor.department | Neurology Department, Brain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands | en |
dc.identifier.journal | Clinical Cancer Research | en |
dc.description.note | en] |